- Transition Therapeutics' (NASDAQ:TTHI +0.3%) neuropsychiatric drug candidate, ELND005, demonstrated an acceptable safety and tolerability profile in a Phase 2a study in young adults with Down syndrome at a dose of 250 mg once or twice per day. The company will be discussing the future development of the product candidate with investigators to determine a path forward, including evaluating a higher dose.
- ELDN005 is an orally bioavailable small molecule being investigated for multiple neuropsychiatric indications including agitation and aggression in Alzheimer's disease (AD) patients. The FDA designated ELDN005 Fast Track for the treatment of neuropsychiatric symptoms in AD in July 2013.